PANDUAN Masyarakat

Pelan Kawalan Perubahan yang Ditentukan FDA untuk Peranti AI

An FDA predetermined change control plan (PCCP) describes specified planned modifications to a medical device, how the manufacturer will develop and validate them, and how their effects will be assessed.

Dengar panduan iniAI-diceritakan · ~3 min

Pada halaman ini3 min dibaca
  1. Gambaran keseluruhan
  2. Menyelam dalam
  3. Pelaksanaan Dunia Sebenar
  4. The Future of FDA Predetermined Change Control Plans for AI Devices
  5. Mempraktikkannya
  6. Teruskan Meneroka
  7. Soalan lazim

Gambaran keseluruhan

FDA reviews an AI-device PCCP as part of a marketing submission. The plan can support defined future changes without a separate submission for each change, within its authorized scope.

Menyelam dalam

A PCCP is a planned change-management component of a medical-device marketing submission. FDA’s August 2025 final guidance gives recommendations for PCCPs tailored to AI-enabled device software functions, including the device constituent part of device-led combination products reviewed through 510(k), De Novo, and PMA pathways. FDA reviews the proposed plan with the marketing submission to assess whether the described changes can be made while maintaining a reasonable assurance of safety and effectiveness. A PCCP does not permit unrestricted changes. The guidance organizes the plan around three elements: a description of planned modifications, a modification protocol for developing, validating, and implementing those changes, and an impact assessment addressing benefits and risks. The planned changes need defined boundaries. The protocol should state methods, acceptance criteria, data controls, validation, implementation safeguards, and monitoring appropriate to the device and proposed change. The impact assessment should explain how changes could affect safety and effectiveness, including interactions among modifications. Vague promises to “retrain as needed” do not provide a meaningful boundary or evidence plan. After FDA authorizes a PCCP, a manufacturer may implement modifications that conform to the authorized plan without a new marketing submission for each described modification. It must still follow applicable quality-system, labeling, reporting, and other regulatory obligations. A proposed change outside the PCCP, or one that fails its protocol, requires a separate regulatory assessment. Depending on the change and device pathway, a new 510(k), De Novo, PMA supplement, or other action may be required. PCCP authorization therefore changes the route for a bounded category of updates; it does not exempt a product from device regulation. The 2025 guidance is final agency guidance and expresses FDA’s current recommendations; guidance does not itself establish legally enforceable responsibilities unless specific statutory or regulatory requirements apply. Manufacturers should distinguish this AI-focused guidance from earlier draft documents and from joint international PCCP guiding principles. Align scope, evidence, risk controls, and monitoring with the device and patient context.

Pelaksanaan Dunia Sebenar

A radiology software maker proposes a bounded retraining method, validation protocol, and performance limits for a device intended to detect a defined finding.

A manufacturer specifies which input hardware can be added and how each configuration will be tested before release.

A change to a model’s intended population falls outside the authorized PCCP, so the manufacturer evaluates whether a new marketing submission is required.

A quality team links each released model update to the authorized plan, validation evidence, risk review, and post-market monitoring record.

The Future of FDA Predetermined Change Control Plans for AI Devices

FDA’s guidance supports iterative improvement under defined controls while retaining review of safety and effectiveness. As experience accumulates, agency recommendations, standards, and accepted evidence methods may evolve. Manufacturers should check the current FDA guidance and submission requirements when preparing a plan, and reassess when the device, intended population, or update method changes. A successful PCCP depends on evidence and operational controls after clearance as well as the initial submission. Schedule a review when FDA revises the guidance or the device’s update method changes.

Mempraktikkannya

Mengapa ia penting

  • Risiko dan keselamatan. Kemudaratan AI malapetaka dan setiap hari bergantung pada siapa yang memahami risiko dan siapa yang boleh bertindak.
  • Keputusan yang lebih jelas. Celik awam dan profesional membentuk sama ada dasar keselamatan yang kukuh adalah mungkin dari segi politik.
  • Memotong keterujaan. Penjelasan yang jelas mengurangkan tangkapan oleh gembar-gembur, PR makmal dan teater etika yang tidak jelas.

Berhati-hati untuk

  • Merawat risiko kewujudan sebagai sci-fi manakala sebatian keupayaan.
  • Mengelirukan keselamatan produk permukaan dengan penjajaran di bawah autonomi tinggi.
  • Meninggalkan khalayak bukan Inggeris dan bukan pakar dengan hanya sumber berkualiti rendah.

Langkah seterusnya

  1. Asingkan bahaya produk, penyalahgunaan dan kehilangan kawalan / risiko salah jajaran.
  2. Tanya apakah bukti yang akan mengubah pandangan anda tentang garis masa dan keterukan.
  3. Lebih suka sumber utama dan penilaian konkrit berbanding tuntutan pemasaran.
  4. Kenal pasti satu laluan tindakan: kerjaya, dasar, pembiayaan atau kemahiran — bukan sahaja kesedaran.

Teruskan Meneroka

Newsletter percuma

Dapatkan taklimat AI harian

Tiga cerita AI yang disahkan setiap pagi hari bekerja, ditulis dalam Bahasa Inggeris biasa. Percuma selamanya, tiada iklan.

Satu e-mel setiap hari bekerja. Berhenti melanggan dalam satu klik. Kami tidak pernah menjual atau berkongsi alamat anda.

Uji diri anda

Take the FDA Predetermined Change Control Plans for AI Devices quiz

Maklum balas segera pada setiap jawapan, dan sijil yang boleh dikongsi dengan ID yang boleh disahkan sebaik sahaja anda lulus kursus.

Mulakan kuiz

Sokong pendidikan AI percuma. AI Understanding ialah pertubuhan bukan keuntungan 501(c)(3) — tiada iklan, tiada bayaran dinding, selamanya. Buat derma

Soalan lazim

What is FDA Predetermined Change Control Plans for AI Devices?

An FDA predetermined change control plan (PCCP) describes specified planned modifications to a medical device, how the manufacturer will develop and validate them, and how their effects will be assessed. FDA reviews an AI-device PCCP as part of a marketing submission. The plan can support defined future changes without a separate submission for each change, within its authorized scope.

Which three elements form the core of an AI-device PCCP?

FDA’s final guidance describes planned modifications, a protocol for implementing them, and an assessment of their impact.

When does FDA review a proposed PCCP?

FDA reviews the PCCP as part of the relevant marketing submission.

What does PCCP authorization allow a manufacturer to do?

The plan can support specified future modifications without a new marketing submission for each change, if they follow the authorized plan.

A manufacturer wants to add a new patient population that its PCCP did not describe. What is the appropriate next step?

A change outside the authorized scope needs a regulatory assessment and may require a new submission.

Which version of FDA’s AI-device PCCP guidance is final?

FDA identifies its tailored final guidance as issued in August 2025.